Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Ballast Advisors LLC

Ballast Advisors LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,455 shares of the company’s stock after acquiring an additional 1,771 shares during the period. Ballast Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,587,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Victory Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC increased its position in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC lifted its stake in Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after buying an additional 30,420 shares during the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $86,000. Finally, Talbot Financial LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $4,066,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 13th. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Down 0.3 %

Shares of NVO stock opened at $78.73 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a market cap of $353.32 billion, a PE ratio of 23.93, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The business’s fifty day moving average is $83.53 and its 200-day moving average is $101.66. Novo Nordisk A/S has a 1 year low of $73.80 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.